Aurigene’s Dr Kesavan Balakumaran shares insights on scalable peptide manufacturing at TIDES Europe 2025

New Delhi: Dr. Kesavan Balakumaran, Group Leader – Analytical Research at Aurigene Pharmaceutical Services Limited, delivered a presentation at TIDES Europe 2025, held in Basel, Switzerland, highlighting modern approaches to the development and manufacturing of peptide therapeutics.

His talk, titled “Modern Methodologies for the Design, Synthesis, Characterization, and Scale-Up of Novel Peptides,” focused on how contract development and manufacturing organizations (CDMOs) play a critical role in enabling the reliable, scalable, and cost-effective production of peptide-based medicines.

Peptides continue to gain importance across multiple therapeutic areas, driving the need for robust manufacturing strategies that can support development from early-stage research through commercial production. During the session, Dr. Balakumaran discussed how flexible manufacturing platforms, combined with strong analytical capabilities, help address the challenges associated with complex peptide molecules.

The presentation highlighted the importance of selecting the right development approach based on project requirements, timelines, and scale, enabling smoother technology transfer and consistent product quality.

Dr. Balakumaran outlined how Aurigene Pharmaceutical Services Limited integrates discovery, development, manufacturing expertise to support peptide programs at various stages. Key themes included the use of adaptable manufacturing strategies to support both early-phase and large-scale requirements; role of advanced purification and analytical techniques in ensuring product quality and consistency; and the differences in value derived among the SPPS, LPPS and Hybrid approaches.

Real-world examples were used to demonstrate how these capabilities can be applied to well-established peptide molecules, illustrating Aurigene’s experience in translating complex processes into scalable manufacturing solutions. The session underscored the evolving role of CDMOs as strategic partners rather than service providers, supporting pharmaceutical and biotechnology companies with customized solutions tailored to their development goals. By combining technical depth with operational flexibility, Aurigene aims to help customers accelerate development timelines while maintaining high quality standards.